KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short term Debt (2016)

Historic Short term Debt for Vertex Pharmaceuticals (VRTX) over the last 6 years, with Q4 2016 value amounting to $300.0 million.

  • Vertex Pharmaceuticals' Short term Debt rose 32078.1% to $300.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $300.0 million, marking a year-over-year increase of 32078.1%. This contributed to the annual value of $300.0 million for FY2016, which is 32078.1% up from last year.
  • Vertex Pharmaceuticals' Short term Debt amounted to $300.0 million in Q4 2016, which was up 32078.1% from $297.8 million recorded in Q3 2016.
  • Over the past 5 years, Vertex Pharmaceuticals' Short term Debt peaked at $300.0 million during Q4 2016, and registered a low of $14.2 million during Q4 2014.
  • Its 3-year average for Short term Debt is $140.3 million, with a median of $108.8 million in 2015.
  • Data for Vertex Pharmaceuticals' Short term Debt shows a peak YoY increase of 41681.94% (in 2016) and a maximum YoY decrease of 32078.1% (in 2016) over the last 5 years.
  • Over the past 3 years, Vertex Pharmaceuticals' Short term Debt (Quarter) stood at $14.2 million in 2014, then soared by 401.87% to $71.3 million in 2015, then surged by 320.78% to $300.0 million in 2016.
  • Its Short term Debt was $300.0 million in Q4 2016, compared to $297.8 million in Q3 2016 and $221.6 million in Q2 2016.